-
Mar 27, 2023
-
Abberior has announced that they have placed a super-resolution STED microscope at MBC BioLabs, the leading San Francisco Bay Area biotech incubator network.
Mar 23, 2023
-
VERICHEM LABORATORIES now offers multi-level calibration verification materials for amylase and lipase activity as part of its liquid stable, ready-to-use Enzyme ER™ Verifier Kit.
Mar 19, 2023
-
NADMED has announced that TruDiagnostic partner to launch novel NAD blood test in the United States.
Mar 19, 2023
-
It will provide strategies to de-risk each stage of the R&D pipeline, with particular focus on regulatory drivers, investigatory objectives, and practical concerns that are relevant to toxicologists.
Mar 15, 2023
-
[London, UK] - Clinion, a leading provider of eClinical solutions, has announced the launch of its new AI-powered medical coding solution. This innovative solution is designed to transform the medical coding process for clinical trials, offering a faster, more efficient, and more accurate way to code medical data.
Medical coding is a critical component of clinical trials, as it enables researchers to accurately capture and analyze medical data. However, the process of medical coding can be time-consuming, error-prone, and costly, often leading to delays in the clinical trial process.
Clinion's new AI Medical Coding is set to revolutionize the clinical trial process by leveraging the power of artificial intelligence to automate medical coding. The solution uses advanced machine learning algorithms to analyze medical data and assign the appropriate medical codes, significantly reducing the time and effort required for manual coding.
The solution also provides real-time feedback to clinical trial teams, allowing them to make data-driven decisions more quickly and efficiently. With improved accuracy and speed, Clinion's medical coding solution enables clinical trial teams to deliver high-quality results and insights faster than ever before.
"We are thrilled to launch AI Medical Coding, which we believe will transform the clinical trial process," said Manuj Vangipurapu, CEO of Clinion. "By harnessing the power of AI, we can provide clinical trial teams with a faster, more efficient, and more accurate way to code medical data. This will enable our customers to make data-driven decisions more quickly and effectively, ultimately accelerating the drug development process and bringing new treatments to patients faster."
Clinion's medical coding solution is the latest addition to its suite of eClinical solutions, which include EDC, RTSM, ePRO, eConsent and CTMS. sWith over 500+ clinical trials successfully conducted using its solutions, Clinion is the go-to partner for companies seeking to streamline their clinical trial process and bring new treatments to market faster.
For more information on Clinion's new AI-powered medical coding solution, please visit clinion.com.
About Clinion
Clinion is a global clinical technology company that offers AI-enabled eClinical solutions consisting of EDC, RTSM, CTMS, eCOA and Document Automation that cover the entire clinical trial lifecycle. Clinion is committed to innovating the future of clinical trials through AI/ML and empowering its partners to manage trials more efficiently at lesser costs. For more information, please visit www.clinion.com.
Mar 14, 2023
-
Discover the top 5 clinical trial technology trends in 2023. From wearables to AI, Digital Patient engagement tools and techniques that are shaping the future of clinical research
Mar 14, 2023
-
Advancing the 150-year-old practice of pathology to improve patient care
Mar 12, 2023
-
bioMérieux, a world leader in in vitro diagnostics for 60 years, is pleased to announce the availability of GENE-UP PRO GENDER ID and GENE-UP PRO HOP LATENT VIROID (HLVd) quality control solutions. The addition of these offerings strengthens the company’s comprehensive portfolio of cannabis microbial testing solutions to provide enhanced control of the cannabis cultivation process risk, creating efficiencies and boosting the bottom line from seed to sale. Thanks to rapid detection with a simple workflow, both solutions empower cultivators to act on infected plants to safeguard the health of crops to maximize yield output.
Mar 12, 2023
-
MoU signed to develop advanced diagnostic solutions for health conditions including diabetic foot infections – reducing risk of complications and AMR
Mar 12, 2023
-
Mar 12, 2023
-
Mar 11, 2023
-
Providing a comprehensive digital diagnostic pathology system for enhanced clinical utility
Mar 7, 2023
-
Halteres Associates, a leading bioscience consultancy that provides strategic and tactical services in the areas of diagnostics, medical devices, and life science research to clients of all sizes, today has launched season one of their new podcast series, Halteres Presents. New episodes of season one of Halteres Presents will be released weekly on Apple and Spotify. Season two is already in the works and is set to be released later in 2023.
Apple Podcasts Link: https://podcasts.apple.com/us/podcast/halteres-presents/id1675559229
Spotify Link: https://open.spotify.com/show/436uwcDjTxAlOIiVXsGUDJ?si=6f71d5d23e0b4fd4
Mar 6, 2023
-
TARRYTOWN, N.Y. - March 2, 2023 - The IMA Group (IMA), a leading technology-enabled provider of clinical trials and medical and psychological screening and evaluation services, announced today that industry veteran Dana Poff would lead IMA’s Clinical Research Division as Executive Vice President. IMA Clinical Research is a flexible, full-service clinical trial network consisting of geographically diverse clinical trial sites and over 150 satellite sites that conduct site-based, hybrid and decentralized clinical trials.
Poff, a high-profile leader in the clinical trial space, brings over 30 years of clinical trial experience to IMA, having held senior level positions overseeing global project management, strategic alliances and clinical operations for ICON, plc.
Mar 5, 2023
-
Mar 2, 2023
-
Mar 2, 2023
-
Mar 2, 2023
-
Mar 2, 2023
-
Coordination chemistry investigates the characteristics of coordination compounds formed by the interaction between metal atoms or ions and inorganic, organic ions or molecules, as well as their bonding, structure, reaction, classification, and preparation.
Mar 1, 2023